| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Nutraceutical Ingredients | 20 |
$500 |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Novartis has a current Overall Rating of A (Highest Rating). | 7 |
$25 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Cancer Therapies | 23 |
$500 |
| 28-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (NVS). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (NVS). | 5 |
$18 |
| 28-Nov-2009 | Standard & Poor's STARS Report |
N/A
| Novartis AG ADS | 8 |
$35 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | NOVARTIS AG ADS (NVS=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | NOVARTIS AG ADS (NVS=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for NVS. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ABT , AZN , GSK , MRK , NVS , PFE , RHHBY -- DRUGS | 3 |
$4 |
1.48% Nasdaq 
Research Reports
